The orders for the company's emphysema treatment are worth NIS 15 million in 2010.

After obtaining marketing approval from Brazil's National Health Surveillance Agency (Anvisa) for its intravenous Alpha-1 Antitrypsin (AAT) protein for the treatment of congenital emphysema, Kamada Ltd. (TASE: KMDA) today announced that it has obtained export orders for AAT for the treatment of congenital emphysema and cystic fibrosis for patients lacking the AAT protein, type D emphysema, and to vaccinate against fetal hemolytic disease, a fatal blood disease.